On Nov 08, major Wall Street analysts update their ratings for $Cencora (COR.US)$, with price targets ranging from $256 to $290.
Morgan Stanley analyst Erin Wright maintains with a hold rating, and adjusts the target price from $242 to $256.
Barclays analyst Stephanie Davis maintains with a buy rating, and adjusts the target price from $263 to $290.
UBS analyst Kevin Caliendo maintains with a buy rating, and adjusts the target price from $267 to $285.
Evercore analyst Elizabeth Anderson CFA maintains with a buy rating, and adjusts the target price from $250 to $285.
Furthermore, according to the comprehensive report, the opinions of $Cencora (COR.US)$'s main analysts recently are as follows:
The company exhibited a modest operational outperformance, buoyed by robust U.S. Healthcare outcomes that were somewhat counterbalanced by weaker International performance.
The company delivered another solid report, guided favorably, and announced a very intriguing managed service organization deal in a new field for distributors, specifically targeting retina care specialists.
Here are the latest investment ratings and price targets for $Cencora (COR.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
